GlassScriptPhysician profile
Wakana Saeki
NPI 1558314096
$2,778.82
in general payments reported to CMS, 2019-2025
30 companies · $682 in 2025
The $682 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $116 · 2021: $324 · 2022: $346 · 2023: $356 · 2024: $721 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $380.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $310.71 | 2019-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $302.52 | 2019-2025 | |
| Lilly USA, LLC | $252.27 | 2019-2025 | Mounjaro, Zepbound, Baqsimi |
| Amgen INC. | $223.92 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.95 | 2019-2024 | Jardiance, Cyltezo, Synjardy |
| Exact Sciences Corporation | $157.81 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $127.88 | 2019-2021 | |
| Pfizer INC. | $106.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $96.10 | 2021-2024 | Arexvy, Shingrix |
| Gilead Sciences, INC. | $69.78 | 2022 | |
| Mayne Pharma Commercial LLC | $62.95 | 2023-2024 | |
| Madrigal Pharmaceuticals | $45.78 | 2025 | Rezdiffra |
| Sanofi-Aventis U.S. LLC | $45.74 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $43.42 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $42.25 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $42.15 | 2025 | Gemtesa |
| Medtronic, INC. | $40.24 | 2022 | |
| Genzyme Corporation | $38.49 | 2023 | |
| Nevro Corp. | $35.52 | 2024 | Senza |
| Aimmune Therapeutics, INC. | $31.74 | 2025 | Vowst |
| Sanofi Pasteur INC. | $26.40 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.81 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.48 | 2021 | |
| Biosense Webster, INC. | $18.60 | 2021 | |
| Ibsa Pharma INC. | $15.51 | 2023 | Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $15.18 | 2025 | Gvoke Hypopen |
| Lupin INC. | $15.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.75 | 2021 | |
| Organon LLC | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wakana Saeki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.